Signaturefd LLC Buys 12,028 Shares of Haleon plc (NYSE:HLN)

Signaturefd LLC increased its position in Haleon plc (NYSE:HLN) by 9.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 135,095 shares of the company’s stock after purchasing an additional 12,028 shares during the period. Signaturefd LLC’s holdings in Haleon were worth $1,289,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HLN. Natixis Advisors LLC grew its stake in Haleon by 142.5% in the third quarter. Natixis Advisors LLC now owns 1,473,767 shares of the company’s stock worth $15,593,000 after purchasing an additional 866,070 shares during the period. Thrivent Financial for Lutherans grew its stake in Haleon by 69.0% in the third quarter. Thrivent Financial for Lutherans now owns 55,593 shares of the company’s stock worth $588,000 after purchasing an additional 22,701 shares during the period. PNC Financial Services Group Inc. grew its stake in Haleon by 3.1% in the third quarter. PNC Financial Services Group Inc. now owns 211,326 shares of the company’s stock worth $2,236,000 after purchasing an additional 6,381 shares during the period. West Family Investments Inc. purchased a new stake in shares of Haleon in the third quarter worth $143,000. Finally, Prospera Private Wealth LLC purchased a new stake in shares of Haleon in the third quarter worth $57,000. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Trading Down 0.1 %

Shares of NYSE:HLN opened at $10.30 on Wednesday. Haleon plc has a 1 year low of $7.99 and a 1 year high of $10.80. The stock’s fifty day moving average price is $9.79 and its 200-day moving average price is $9.88. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The company has a market cap of $46.61 billion, a P/E ratio of 30.28, a PEG ratio of 2.82 and a beta of 0.25.

Haleon (NYSE:HLN) last posted its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The company had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. Sell-side analysts expect that Haleon plc will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The company also recently announced a — dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be issued a $0.1166 dividend. This is an increase from Haleon’s previous — dividend of $0.05. The ex-dividend date of this dividend is Friday, April 25th. This represents a yield of 1.6%. Haleon’s dividend payout ratio is currently 58.97%.

Analyst Upgrades and Downgrades

HLN has been the topic of a number of recent research reports. Hsbc Global Res cut Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Haleon in a research note on Monday, March 3rd. Sanford C. Bernstein downgraded Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. HSBC reaffirmed a “hold” rating on shares of Haleon in a report on Wednesday, March 5th. Finally, Morgan Stanley downgraded Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Six investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.